These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21568322)

  • 1. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
    J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4.
    Nakamura Y; Umehara T; Nakano K; Jang MK; Shirouzu M; Morita S; Uda-Tochio H; Hamana H; Terada T; Adachi N; Matsumoto T; Tanaka A; Horikoshi M; Ozato K; Padmanabhan B; Yokoyama S
    J Biol Chem; 2007 Feb; 282(6):4193-201. PubMed ID: 17148447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
    Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
    BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural implications for K5/K12-di-acetylated histone H4 recognition by the second bromodomain of BRD2.
    Umehara T; Nakamura Y; Wakamori M; Ozato K; Yokoyama S; Padmanabhan B
    FEBS Lett; 2010 Sep; 584(18):3901-8. PubMed ID: 20709061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
    Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
    J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain.
    Umehara T; Nakamura Y; Jang MK; Nakano K; Tanaka A; Ozato K; Padmanabhan B; Yokoyama S
    J Biol Chem; 2010 Mar; 285(10):7610-8. PubMed ID: 20048151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex.
    Tripathi S; Mathur S; Deshmukh P; Manjula R; Padmanabhan B
    PLoS One; 2016; 11(5):e0156344. PubMed ID: 27243809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
    Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
    Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthyridines as novel BET family bromodomain inhibitors.
    Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
    ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET-Family Bromodomains Can Recognize Diacetylated Sequences from Transcription Factors Using a Conserved Mechanism.
    Patel K; Solomon PD; Walshe JL; Ford DJ; Wilkinson-White L; Payne RJ; Low JKK; Mackay JP
    Biochemistry; 2021 Mar; 60(9):648-662. PubMed ID: 33620209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
    Chung CW; Dean AW; Woolven JM; Bamborough P
    J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bromodomains of BET family proteins can recognize diacetylated histone H2A.Z.
    Patel K; Solomon PD; Walshe JL; Low JKK; Mackay JP
    Protein Sci; 2021 Feb; 30(2):464-476. PubMed ID: 33247496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
    J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.